Systemic chemotherapy of hepatocellular carcinoma - Korean experience

Oncology

Volumn 75, Issue SUPPL. 1, 2008, Pages 114-118

  Lee, Han Chu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma, advanced stage; Hepatocellular therapies; Sorafenib

Indexed keywords

ALPHA2B INTERFERON; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PLACEBO; SORAFENIB; UFT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KOREA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; KOREA; LIVER NEOPLASMS;

EID: 58149097315     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173432     Document Type: Conference Paper

References (21)

1. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
2. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon-alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
3. Jang MK, Lee HC, Kim IS, Lim YS, Chung YH, Lee YS, Sung KB, Yoon HK, Ko GY, Kim AY, Suh DJ: Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization. J Gastroenterol Hepatol 2004;19:1074-1080.
4. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991.
5. Sim MK, Kim DY, Park JY, Kim JK, Kim SA, Ahn SH, Chon CY, Moon YM, Won JY, Lee DY, Han KH: Efficacy of repeated hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma with portal vein tumor thrombosis. Korean J Hepatol 2005;11:268-274.
6. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595.
7. Song HG, Lee HC, Song BC, Chung YH, Lee YS, Yoon HK, Sung KB, Suh DJ: Efficacy of repeated arterial infusion of cisplatin and 5-fluorouracil via a percutaneously implantable port system in advanced hepatocellular carcinoma. Korean J Hepatol 2001;7:61-67.
8. Jang BK, Kwon KM, Chung WJ, Park KS, Cho KB, Hwang JS, Ahn SH, Kim GC, Kim YH, Choi JS, Kwon JH: Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin. Korean J Hepatol 2004;10:271-278.
9. Lim TY, Cheong JY, Cho SW, Sim SJ, Kim JS, Choi SJ, Choi JW, Kwon HC, Lee KM, Kim JK, Won JH, Yoo BM, Lee KJ, Hahm KB, Kim JH: Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis. Korean J Hepatol 2006;12:65-73.
10. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-137.
11. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K: Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54:385-390.
12. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006;6:3.
13. Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS: Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006;57:436-442.
14. Lee JL, Ryu MH, Chang HM, Kim TW, Lee SS, Sym SJ, Kim MK, Kim KM, Lee JS, Kang YK: Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. J Gastroenterol Hepatol 2008;23:811-816.
15. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. J Hepatol 1993;18:168-172.
16. Friedman MA: Primary hepatocellular cancer - present results and future prospects. Int J Radiat Oncol Biol Phys 1983;9:1841-1843.
17. Lai CL, Wu PC, Chan GC, Lok AS, Lin HG: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
18. Lin DY, Lin SM, Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S319-S328.
19. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H: Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975;36:1250-1257.
20. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L: Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985;56:2751-2755.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.